Trial Profile
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Pegfilgrastim
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms GIOTTO
- 01 Oct 2022 Primary endpoint (Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.) has not been met according to results published in the Hematological Oncology
- 01 Oct 2022 Results published in the Hematological Oncology
- 01 Jun 2022 Status changed from completed to discontinued.